The changing landscape in Germany regarding HTA assessments
18 May 2016
The changing landscape in Germany regarding HTA assessments
The German landscape for introduction of new technologies and drugs is changing dramatic. For drugs, the introduction of the Amnog process has been a drastic change. Now the medical devices are undergoing a similar drastic change, where new medical technologies coming to market through the innovation funding pathway have to go through a benefit assessment.
Below are statistics regarding the development of HTA activity in Germany. It does not only include HTAs, but also the important guidelines published from G-BA.
Learn more about our services here: